Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Self-Triage Use, Subsequent Healthcare Utilization, and Diagnoses: A Retrospective Study of Process and Clinical Outcomes Following Self-Triage and Self-Scheduling for Ear or Hearing Symptoms
North, Frederick , Jensen, Teresa B. , Stroebel, Robert J. , Nelson, Elissa M , Johnson, Brenda J , Thompson, Matthew C , Pecina, Jennifer L. , Crum, Brian A. , Pecina, Jennifer , Crum, Brian A , Thompson, Matthew C

Mayo Clinic

Health Services Research and Managerial Epidemiology | April 19, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/23333928231168121 | PMID 37101803 Get It

Background Self-triage is becoming more widespread, but little is known about the people who are using online self-triage tools and their outcomes. For self-triage researchers, there are significant barriers to capturing subsequent healthcare outcomes. Our integrated healthcare system was able to capture subsequent healthcare utilization of individuals who used self-triage integrated with self-scheduling of provider visits. Methods We retrospectively examined healthcare utilization and diagnoses after patients had used self-triage and self-scheduling for ear or hearing symptoms. Outcomes and counts of office visits, telemedicine interactions, emergency department visits, and hospitalizations were captured. Diagnosis codes associated with subsequent provider visits were dichotomously categorized as being associated with ear or hearing concerns or not. Nonvisit care encounters of patient-initiated messages, nurse triage calls, and clinical communications were also captured. Results For 2168 self-triage uses, we were able to capture subsequent healthcare encounters within 7 days of the self-triage for 80.5% (1745/2168). In subsequent 1092 office visits with diagnoses, 83.1% (891/1092) of the uses were associated with relevant ear, nose and throat diagnoses. Only 0.24% (4/1662) of patients with captured outcomes were associated with a hospitalization within 7 days. Self-triage resulted in a self-scheduled office visit in 7.2% (126/1745). Office visits resulting from a self-scheduled visit had significantly fewer combined non-visit care encounters per office visit (fewer combined nurse triage calls, patient messages, and clinical communication messages) than office visits that were not self-scheduled (−0.51; 95% CI, −0.72 to −0.29; P < .0001). Conclusion In an appropriate healthcare setting, self-triage outcomes can be captured in a high percentage of uses to examine for safety, patient adherence to recommendations, and efficiency of self-triage. With the ear or hearing self-triage, most uses had subsequent visit diagnoses relevant to ear or hearing, so most patients appeared to be selecting the appropriate self-triage pathway for their symptoms.
RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion
Meneses, Kayleah M. , Pandya, Prita , Lindemann, Jennifer A. , Al-Qasrawi, Dania S. , Argo, Ryan A. , Weems, Celeste M. , Beetler, Danielle J. , Vijay, Geraldine V. , Yan, Irene K. , Wolfram, Joy , Justilien, Verline , Patel, Tushar , Justilien, Verline , Wolfram, Joy , Pandya, Prita , Patel, Tushar

Mayo Clinic

Cancer Research Communications | April 17, 2023 | Volume: 3 | Issue: 4 | Pages: 607-620

10.1158/2767-9764.crc-22-0425 | PMID 37077938 Get It

Cancer stem cells (CSC) within non–small cell lung carcinoma (NSCLC) tumors drive NSCLC progression, metastasis, relapse, and intrinsic chemoresistance. Understanding the mechanisms that support the malignant phenotypes of NSCLC CSCs may provide insights for improved NSCLC therapeutic interventions. Here, we report that expression of RAB27B, a small GTPase, is significantly upregulated in NSCLC CSCs when compared with bulk cancer cells (BCC). Short hairpin RNA–mediated knockdown of RAB27B leads to a loss of stem cell marker gene expression and reduced NSCLC spheroid growth, clonal expansion, transformed growth, invasion, and tumorigenicity. We find that NSCLC CSCs secrete significantly more extracellular vesicles (EV) than BCCs, and that this is RAB27B-dependent. Furthermore, CSC-derived EVs, but not BCC-derived EVs, induce spheroid growth, clonal expansion, and invasion in BCCs. Finally, RAB27B is required for CSC-derived EV-induced stemness in BCCs. Taken together, our results indicate that RAB27B is required for maintenance of a highly tumorigenic, cancer-initiating, invasive stem-like cell population in NSCLC and RAB27B is involved in propagating EV-mediated communication from NSCLC CSCs to BCCs. Our findings further suggest that inhibition of RAB27B-dependent EV secretion may be a potential therapeutic strategy for NSCLC. Significance: Expression of RAB27B in CSCs leads to elevated levels of EVs that mediate communication between CSCs and BCCs that maintains a stem-like phenotype in NSCLC cells.
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
Bhatt, Vijaya Raj , Ulrich, Angela M. , Uy, Geoffrey L. , Stone, Richard M. , Stock, Wendy , Ojelabi, Michael Olayiwola , Yin, Jun , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Baer, Maria R. , Chow, Selina , Jatoi, Aminah , Ojelabi, Michael O , Klepin, Heidi D , Le-Rademacher, Jennifer G , Stock, Wendy , Bhatt, Vijaya Raj , Uy, Geoffrey , Klepin, Heidi D. , Le‐Rademacher, Jennifer

Mayo Clinic

JCO Oncology Practice | April 14, 2023 | Volume: 19 | Issue: 6 | Pages: e877-e891

10.1200/op.22.00822 | PMID 37058684 Get It

PURPOSE: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive chemotherapy trials at community versus academic cancer centers. METHODS: We used data from the Alliance for Clinical Trials in Oncology phase III trials that enrolled patients age ≥ 60 years with newly diagnosed AML between 1998 and 2002 in the Cancer and Leukemia Group B (CALGB) 9720 trial and between 2004 and 2006 in the CALGB 10201 trial. Centers funded by the NCI Community Oncology Research Program were identified as community cancer centers; others were designated as academic cancer centers. Logistic regression models and Cox proportional hazards models were used to compare 1-month mortality and overall survival (OS) by center type. RESULTS: Seventeen percent of the 1,170 patients were enrolled in clinical trials in community cancer centers. The study results demonstrated comparable rates of grade ≥3 adverse events (97% v 93%), 1-month mortality (19.1% v 16.1%), and OS (43.9% v 35.7% at 1 year) between community versus academic cancer centers, respectively. After adjusting for covariates, 1-month mortality (odds ratio, 1.40; 95% CI, 0.92 to 2.12; P = .11) and OS (hazard ratio, 1.04; 95% CI, 0.88 to 1.22; P = .67) were not statistically different among patients treated in community versus academic cancer centers. CONCLUSION: An older patient population, who have complex health care needs, can be successfully treated on intensive chemotherapy trials in select community cancer centers with outcomes comparable with that achieved at academic cancer centers.
Abstract LB112: Increasing clinical trials diversity through Community Research Registry (CoRR): The Community Champions for clinical trials program
Odedina, Folakemi T., Willis, Floyd B. , Crook, Jennifer , Asto-Flores, Emelina , Johnson, Kim Barbel, Workman, Chad

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: LB112-LB112

10.1158/1538-7445.am2023-lb112 Get It

Abstract Introduction: The lack of representation of minoritized and marginalized (MaM) populations in Clinical Trials (CTs) has been noted as one of the key factors that contribute to cancer health disparities. The challenges of CT diversity are multifactorial, including barriers at the personal, provider, health systems and protocol levels. Guided by a vision of developing and implementing inclusive CTs that address the priorities identified by our communities, we created a Community Research Registry (CoRR) with three primary aims: 1. Maintaining a CoRR database of participants who may be eligible for participation in future CTs; 2. Using the database, facilitate matching of MaM populations to Clinical Trials; and 3. Facilitating access of MaM populations to CTs. Methodology: The Mayo Clinic CoRR is IRB-approved and was implemented in 2022 through bidirectional engagement of communities, partnership with community leaders to foster community input, dissemination of CT information to high-risk communities, and use of evidence-based education materials for community outreach. Participants are recruited in MaM communities (including clinics, churches, health events) and through effective use of social media. Organized events for recruitment include: 1. CT education; 2. provision of culturally tailored CT educational materials and T-shirts; and 3. data collection from those who consent to be part of the registry. The inclusion criteria for the registry are adults and ability to read and write in English or Spanish. Informed consent is obtained prior to completion of the registry form and participants receive $10 incentive. The data is collected using REDCap, and includes name and contact information of participants, demographic information, chronic disease status and explicit consent to be contacted for future research studies (with option to state type of study). New Unpublished Data: Within 7 months of CoRR implementation, 184 MaM participants signed up with 92% Black (including 10% African immigrants), 7% Hispanic, 69% female, median age of 64 years, 24% rural residents, and most of the participants had high school level education. Over 30% of participants reported medical history of hypertension, high cholesterol, arthritis and/or diabetes. 8% reported cancer. Approved investigators (with appropriate community engagement training) have direct access to de-identified CoRR information though Tableau for the purpose of estimating participants for their study. Tableau has been found to be effective for investigators to explore the database for CT/research match. All requests for participants matching are approved by a CoRR Board that includes community representatives, prior to matching. CoRR CT matching is now in its pilot phase, with Mayo Clinic studies identified for matching. Conclusion: The feasibility of the CT CoRR has been established, and has led to over 20 CoRR Champion organizations, including churches, sororities, fraternities, and the American Legion Post. Citation Format: Folakemi T. Odedina, Floyd Willis, Jennifer Crook, Emelina Asto-Flores, Kim Barbel Johnson, Chad Workman, Mayo Clinic Comprehensive Cancer Center CommunityOutreach and Engagement. Increasing clinical trials diversity through Community Research Registry (CoRR): The Community Champions for clinical trials program [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB112.
Quantitative Sleep Electroencephalogram in Parkinson’s Disease: A Case-Control Study
Memon, Adeel , Catiul, Corina , Irwin, Zachary T. , Pilkington, Jennifer, Memon, Raima , Joop, Allen , Wood, Kimberly H. , Amara, Amy W. , Memon, Raima A, Cutter, Gary , Miocinovic, Svjetlana

Mayo Clinic

Journal of Parkinson’s Disease | April 11, 2023 | Volume: 13 | Issue: 3 | Pages: 351-365

10.3233/jpd-223565 | PMID 37066921 Get It

Background: Sleep disorders are common in Parkinson’s disease (PD) and include alterations in sleep-related EEG oscillations. Objective: This case-control study tested the hypothesis that patients with PD would have a lower density of Scalp-Slow Wave (SW) oscillations and higher slow-to-fast frequencies ratio in rapid eye movement (REM) sleep than non-PD controls. Other sleep-related quantitative EEG (qEEG) features were also examined, including SW morphology, sleep spindles, and Scalp-SW spindle phase-amplitude coupling. Methods: Polysomnography (PSG)-derived sleep EEG was compared between PD participants ( n = 56) and non-PD controls ( n = 30). Following artifact rejection, sleep qEEG analysis was performed in frontal and central leads. Measures included SW density and morphological features of SW and sleep spindles, SW-spindle phase-amplitude coupling, and spectral power analysis in Non-REM (NREM) and REM. Differences in qEEG features between PD and non-PD controls were compared using two-tailed Welch’s t-tests, and correction for multiple comparisons was performed per the Benjamini-Hochberg method. Results: SW density was lower in PD than in non-PD controls (F = 13.5, p’ = 0.003). The PD group also exhibited higher ratio of slow REM EEG frequencies (F = 4.23, p’ = 0.013), higher slow spindle peak frequency (F = 24.7, p’ < 0.002), and greater SW-spindle coupling angle distribution non-uniformity (strength) (F = 7.30, p’ = 0.034). Conclusion: This study comprehensively evaluates sleep qEEG including SW-spindle phase amplitude coupling in PD compared to non-PD controls. These findings provide novel insights into how neurodegenerative disease disrupts electrophysiological sleep rhythms. Considering the role of sleep oscillatory activity on neural plasticity, future studies should investigate the influence of these qEEG markers on cognition in PD.
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
Spencer, Kristen , Pappas, Leontios , Baiev, Islam , Maurer, Jordan R., Bocobo, Andrea Grace, Jain, Apurva, Reyes, Stephanie , Le, Tri Minh , Rahma, Osama E. , Stanton, Jennifer R., DeLeon, Thomas, Roth, Marc, Zhu, Andrew X. , Lennerz, Jochen K. , Iafrate, A. John , Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R. , Lindsey, Stacie , Goff, Laura W. , Mody, Kabir , Shroff, Rachna T. , Kelley, Robin Kate , Javle, Milind , DeLeon, Thomas T, Lennerz, Jochen , Goyal, Lipika , Roberts, Lewis R , Spencer, Kristen , Pappas, Leontios , Zhang, Karen , Jain, Apurva, De Armas, Anaemy Danner , Roth, Marc, Peters, Mary Linton B , Horick, Nora , Borad, Mitesh J. , Goyal, Lipika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 11, 2023 | Volume: 115 | Issue: 7 | Pages: 870-880

10.1093/jnci/djad046 | PMID 37040087 Get It

Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. Methods This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. Results Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P &lt; .00001). However, they were less likely to undergo molecular profiling (50.3% vs 64.3%) or receive liver-directed therapy (17.9% vs 35.7%), targeted therapy (4.7% vs 18.9%), and clinical trial therapy (10.6% vs 24.8%) (all P &lt; .001). In patients with recurrent ECC after surgery, the molecular profiling rate was 64.5%. Patients with advanced ECC had a shorter median overall survival than those with advanced ICC (11.8 vs 15.1 months; P &lt; .001). Conclusions Patients with advanced ECC have low rates of molecular profiling, possibly in part because of insufficient tissue. They also have low rates of targeted therapy use and clinical trial enrollment. While these rates are higher in advanced ICC, the prognosis for both subtypes of cholangiocarcinoma remains poor, and a pressing need exists for new effective targeted therapies and broader access to clinical trials.
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
Tran, Benjamin V. , Moris, Dimitrios , Markovic, Daniela , Zaribafzadeh, Hamed , Lai, Quirino , Florman, Sander , Tabrizian, Parissa , Haydel, Brandy , Ruiz, Richard M., Klintmalm, Göran B. , Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Lerut, Jan , Nguyen, Mindie H. , Viveiros, André , Schaefer, Benedikt , Hoppe‐Lotichius, Maria , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, R. Mark , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Busuttil, Ronald W. , Barbas, Andrew S. , Lai, Quirino , Florman, Sander S , Tabrizian, Parissa , Haydel, Brandy , Klintmalm, Goran , Lee, David D , Taner, Burcin , Hoteit, Maarouf , Levine, Matthew H , Cillo, Umberto , Verna, Elizabeth C , Halazun, Karim J , Tevar, Amit D , Humar, Abhinav , Chapman, William C , Vachharajani, Neeta , Ciccarelli, Olga , Nguyen, Mindie H , Melcher, Marc L , Viveiros, Andre , Schaefer, Benedikt , Hoppe-Lotichius, Maria , Mittler, Jens , Markmann, James F , Rossi, Massimo , Mobley, Constance , Ghobrial, Mark , Schnickel, Gabriel T , Sudan, Debra L , Hong, Johnny C , Rana, Abbas , Jones, Christopher M , Busuttil, Ronald W , Barbas, Andrew S , Agopian, Vatche G , Moris, Dimitrios , Henao, Ricardo , Ruiz, Richard , Taner, C. Burcin , Vitale, Alessandro , Melcher, Marc L. , Carney, Carol A., Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | April 7, 2023 | Volume: 29 | Issue: 7 | Pages: 683-697

10.1097/lvt.0000000000000145 | PMID 37029083 Get It

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients
Kendrick, Michael L. , Smoot, Rory L. , Nagorney, David M. , Truty, Mark J. , Gudmundsdottir, Hallbera , Smoot, Rory L , Yonkus, Jennifer A. , Alva‐Ruiz, Roberto , Warner, Susanne G. , Starlinger, Patrick , Thiels, Cornelius A. , Cleary, Sean P. , Grotz, Travis E.

Mayo Clinic

Journal of the American College of Surgeons | April 7, 2023 | Volume: 237 | Issue: 1 | Pages: 49-57

10.1097/xcs.0000000000000704 | PMID 37026837 Get It

BACKGROUND: Accurate staging prior to resection of pancreatic ductal adenocarcinoma (PDAC) is imperative to avoid unnecessary operative morbidity and oncologic futility in patients with occult intra-abdominal distant metastases. We aimed to determine the diagnostic yield of staging laparoscopy (SL) and to identify factors associated with increased risk of positive laparoscopy (PL) in the modern era. STUDY DESIGN: Patients with radiographically localized PDAC who underwent SL from 2017 to 2021 were retrospectively reviewed. The yield of SL was defined as the proportion of patients with PL, including gross metastases and/or positive peritoneal cytology. Factors associated with PL were assessed using univariate analysis and multivariable logistic regression. RESULTS: Of 1,004 patients who underwent SL, 180 (18%) had PL due to gross metastases (n = 140) and/or positive cytology (n = 96). Patients who had neoadjuvant chemotherapy prior to laparoscopy had lower rates of PL (14% vs 22%, p = 0.002). When the analysis was restricted to chemo-naive patients who had concurrent peritoneal lavage performed, 95 of 419 patients (23%) had PL. In multivariable analysis, PL was associated with younger (<60) age, indeterminate extrapancreatic lesions on preoperative imaging, body/tail tumor location, larger tumor size, and elevated serum CA 19-9 (all p < 0.05). Among patients with no indeterminate extrapancreatic lesions on preoperative imaging, the rate of PL ranged from 1.6% in patients with no risk factors to 42% in young patients with large body/tail tumors and elevated serum CA 19-9. CONCLUSIONS: The rate of PL in patients with PDAC remains high in the modern era. SL with peritoneal lavage should be considered for the majority of patients prior to resection, specifically those with high-risk features, and ideally prior to neoadjuvant chemotherapy.
Lifetime Prevalence of Psychiatric Disorders in Adolescents with Unexplained Weight Loss, Underweight, or Poor Appetite
Witte, Micaela A. , Weber, Cynthia Harbeck, Lebow, Jocelyn , Geske, Jennifer R. , Witte, Nathaniel, Whiteside, Stephen P. H. , Loth, Katie A. , Sim, Leslie , Harbeck Weber, Cynthia, Geske, Jennifer, Whiteside, Stephen, Lebow, Jocelyn , Geske, Jennifer , LeMahieu, Allison

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | April 6, 2023 | Volume: 44 | Issue: 4 | Pages: e277-e283

10.1097/dbp.0000000000001173 | PMID 37020320 Get It

ABSTRACT: Background: When adolescents present with symptoms of unexplained weight loss, underweight, or poor appetite, eating disorders (EDs) are commonly on the list of differential diagnoses. However, the relationship of these symptoms to other psychiatric disorders is often less clear. Methods: Using the Rochester Epidemiology Project database, a retrospective cohort study of adolescents (13–18 years) with billing diagnoses of weight loss, underweight, or loss of appetite was conducted between January 2005 and December 2017. Patients who presented with conditions commonly associated with weight loss, underweight, or poor appetite (e.g., cancer) were excluded. This study sought to examine the proportion of patients who received ED and psychiatric diagnoses within 5 years of the index visit and patient characteristics associated with these diagnoses. Results: Of 884 patients diagnosed with symptoms of unexplained weight loss, underweight, or poor appetite, 662 patients (M age = 15.8; SD = 1.6; 66.0% female) met study criteria. Within 5 years of the index visit, the lifetime prevalence of all psychiatric disorders was 70% (n = 461) and of EDs was 21% (n = 141). For both psychiatric disorders and EDs, sex and race were significantly associated with receiving a diagnosis within 5 years. Decrease in body mass index (BMI) percentile was associated with receiving an ED diagnosis, whereas the highest historical BMI percentile was associated with receiving a psychiatric diagnosis. Conclusion: Patients presenting with symptoms of unexplained weight loss, underweight, or poor appetite are at risk not only for EDs but also for other psychiatric disorders that may require further assessment and follow-up.
Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study
Ligibel, Jennifer A. , Barry, William T., Sella, Tal , Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Emmons, Karen M. , Partridge, Ann H. , Emmons, Karen M. , Ruddy, Kathryn J , Rosenberg, Shoshana , Partridge, Ann H , Zheng, Yue , Greaney, Mary L.

Mayo Clinic

Cancer | April 5, 2023 | Volume: 129 | Issue: 14 | Pages: 2135-2143

10.1002/cncr.34779 | PMID 37016839 Get It

AbstractBackgroundObesity and inactivity are poor prognostic factors in breast cancer, but less is known regarding physical activity (PA) and weight patterns in young breast cancer survivors.MethodsThe Young and Strong Study was a cluster‐randomized trial evaluating education and support interventions for young women (age <45 years) with newly diagnosed breast cancer. Sites were randomized 1:1 to a Young Women's Intervention (YWI) or a contact‐time control physical activity intervention (PAI). Changes in PA and weight were compared between groups using general estimating equations to evaluate clustered binary and Gaussian data.ResultsA total of 467 patients enrolled between July 2012 and December 2013 across 54 sites. Median age at diagnosis was 40 years (range, 22–45). At baseline, median body mass index (BMI) was 25.4 kg/m2 (range, 16.1–61.1), and participants reported a median of 0 minutes (range, 0–2190) of moderate/vigorous PA/week. PA increased significantly over time in both groups (p < .001), with no difference between groups at any time point. BMI increased modestly but significantly (p < .001) over time in both groups. Provider attention to PA was observed in 74% of participants on PAI and 61% on YWI (p = .145) and correlated with PA at 12 months (median 100 min/week of PA in participants with provider attention to PA vs. 60 min/week in those without, p = .016).ConclusionsIn a cohort of young women with breast cancer, rates of obesity and inactivity were high. PA and BMI increased over time and were not impacted by an educational PA intervention. Findings provide important information for developing lifestyle interventions for young breast cancer survivors.